In afternoon trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has bounced back from two disappointing trading days in a row with a push higher. At the time of writing the benchmark index is up 0.1% to 6,193.3 points.
Four shares that have failed to follow the market higher today are listed below. Here’s why they have dropped lower:
The Althea Group Holdings Limited (ASX: AGH) share price has tumbled 6% lower to 61.5 cents. Althea is the latest medicinal cannabis company to hit the ASX boards and listed at a price of 20 cents per share on Friday. I suspect that its incredible gain since listing means that profit taking is weighing on its shares today.
The Australian Pharmaceutical Industries Ltd (ASX: API) share price has plunged almost 10% lower to $1.71. Today’s decline is likely to be attributable to a broker note out of Credit Suisse this morning. According to the note, the broker has downgraded the pharmacy chain operator’s shares to an underperform rating with a reduced price target of $1.55. Credit Suisse fears that its shares could be de-rated next month when its releases its full year results and updates the market on current trading conditions.
The Cedar Woods Properties Limited (ASX: CWP) share price has fallen 4.5% to $5.82. Almost all of today’s decline is attributable to the property developer’s shares going ex-dividend this morning for its final fully franked dividend of 18 cents per share. Eligible shareholders can now look forward to receiving this dividend in their nominated account on October 26.
The Lynas Corporation Ltd (ASX: LYC) share price has fallen a further 2% to $1.60. The rare earths producer’s shares have come under significant selling pressure this week after reports claimed that the Malaysian government was reviewing its operations in the country. The report suggests that a well-known anti-Lynas campaigner has been named as the head of the review. Management advised that “If that appointment is confirmed, then that will raise concerns.”
Scott Phillips has stumbled upon a little-owned stock he believes could be one of the greatest discoveries of his 25 years as a professional investor.
This is your chance to get in early on of what could prove to be a very special investment recommendation. Think about how many investing trends you've missed out on, even though you knew they were going to be big. Don't let that happen again. This is your chance to get in early.
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.